Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Boceprevir
80
CHF
CHF 80.00
In stock
AG-CR1-3735-M0055 mgCHF 80.00
AG-CR1-3735-M01010 mgCHF 120.00
AG-CR1-3735-M05050 mgCHF 250.00
| Product Details | |
|---|---|
| Synonyms | Victrelis; EBP 520; SCH 503034 |
| Product Type | Chemical |
| Properties | |
| Formula |
C27H45N5O5 |
| MW | 519.7 |
| CAS | 394730-60-0 |
| Purity Chemicals | ≥95% (NMR) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (15mg/ml), ethanol (20mg/ml) or DMF (20mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | LHHCSNFAOIFYRV-DOVBMPENSA-N |
| Smiles | [H][C@]1(C2(C)C)[C@]2([H])CN(C([C@H](C(C)(C)C)NC(NC(C)(C)C)=O)=O)[C@]1([H])C(NC(CC3CCC3)C(C(N)=O)=O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- The antiviral agent boceprevir is a protease inhibitor that covalently and reversibly binds to the catalytic site (Ser139) of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A), a serine protease that is essential for viral replication (Ki = 14nM) by cleaving the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. It inhibits the NS3/4A protease in an in vitro HCV replicon system with an EC50 value of 200 nM.
- Boceprevir has been identified as a potential inhibitor of SARS-CoV-2 responsible for COVID-19. It inhibits SARS-CoV-2 viral replication by targeting the viral main protease Mpro (IC50 = 4.13µM).
Product References
- SCH 503034, a mechanism-based inhibitor of Hepatitis C Virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells: B.A. Malcolm, et al.; Antimicrob. Agents Chemother. 50, 1013 (2006)
- Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections: S. Venkatraman; Trends Pharmacol. Sci. 33, 289 (2012) (Review)
- The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease: A.Y. Howe & S. Venkatraman; J. Clin. Transl. Hepatol. 1, 22 (2013) (Review)
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease: C. Ma, et al.; bioRxiv (Preprint) (2020)
Related Products
